These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34614035)

  • 1. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models.
    Ghosh S; Krege W; Doerr B; Mischnik M; Pragst I; Dickneite G; Herzog E
    PLoS One; 2021; 16(10):e0258192. PubMed ID: 34614035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
    Lee FM; Chan AK; Lau KK; Chan HH
    Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
    Le Saché F; Le Bonniec B; Gaussem P; Dizier B; Tagzirt M; Godier A; Emmerich J; Samama CM
    Br J Anaesth; 2012 Apr; 108(4):586-93. PubMed ID: 22258204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.
    Dickneite G; Dörr B; Kaspereit F; Tanaka KA
    J Trauma; 2010 May; 68(5):1151-7. PubMed ID: 19996804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 4F-PCC and aPCC time to administration and outcomes for oral anticoagulant-related ICH.
    Lin S; Cunningham B; Mullen C; Simon E; Bice D; Garlock J
    Am J Emerg Med; 2022 Jun; 56():183-187. PubMed ID: 35405470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model.
    Pragst I; Kaspereit F; Dörr B; Dickneite G
    Thromb Res; 2010 Mar; 125(3):272-7. PubMed ID: 19913880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
    Perzborn E; Gruber A; Tinel H; Marzec UM; Buetehorn U; Buchmueller A; Heitmeier S; Laux V
    Thromb Haemost; 2013 Jul; 110(1):162-72. PubMed ID: 23636219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
    Herzog E; Kaspereit FJ; Krege W; Doerr B; van Ryn J; Dickneite G; Pragst I
    Thromb Res; 2014 Sep; 134(3):729-36. PubMed ID: 25084749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
    Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
    J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Comparison of Recombinant Activated Factor VII Versus 4-Factor Prothrombin Complex Concentrate in Cardiac Surgical Patients.
    Faraoni D; Guindi A; Ankola AA; Resheidat A; Binsalamah Z; Teruya J; Savorgnan F; Vener DF
    J Cardiothorac Vasc Anesth; 2024 Feb; 38(2):388-393. PubMed ID: 38129208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
    Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
    Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
    Körber MK; Langer E; Kaufner L; Sander M; Von Heymann C
    Blood Transfus; 2016 Sep; 14(5):481-6. PubMed ID: 27177413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
    Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
    Res Pract Thromb Haemost; 2017 Jul; 1(1):49-56. PubMed ID: 30046673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
    Grottke O; van Ryn J; Spronk HM; Rossaint R
    Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.
    Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J
    Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.